Lauren Ellis
Adult Health · Lima, PANPI 1043661325
Payments from drug & device makers
Across 127 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$321
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$296
- Neurocrine Biosciences, Inc.$278
- Takeda Pharmaceuticals U.S.A., Inc.$198
- Lundbeck LLC$183
- Teva Pharmaceuticals USA, Inc.$162
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,45995%
- Education$1275%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 24 | $321 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $296 |
| Neurocrine Biosciences, Inc. | 16 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $198 |
| Lundbeck LLC | 8 | $183 |
| Teva Pharmaceuticals USA, Inc. | 5 | $162 |
| Axsome Therapeutics, Inc. | 6 | $146 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Corium, LLC | 4 | $116 |
| Alkermes, Inc. | 6 | $108 |
| Incyte Corporation | 1 | $100 |
| Bausch Health US, LLC | 4 | $88 |
| Ironshore Pharmaceuticals Inc. | 3 | $68 |
| Johnson & Johnson | 2 | $67 |
| Sunovion Pharmaceuticals Inc. | 3 | $66 |
| Avanir Pharmaceuticals, Inc. | 3 | $51 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Boston Scientific | 1 | $23 |
| Urovant Sciences Inc | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $20 |
| OWP Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $13 |
How this compares
$2,586 in reported general payments places this provider in the 80th percentile of 899 adult health providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 24 | $122,784 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 25 | $103,909 |
| EliquisApixaban | 134 | $84,223 |
| Risperdal ConstaRisperidone Microspheres | 25 | $32,549 |
| AplenzinBupropion Hbr | 12 | $31,217 |
| XareltoRivaroxaban | 41 | $23,685 |
| LinzessLinaclotide | 39 | $22,977 |
| CaplytaLumateperone Tosylate | 12 | $21,031 |
| RestasisCyclosporine | 57 | $19,969 |
| MyrbetriqMirabegron | 37 | $15,867 |
| GemtesaVibegron | 30 | $15,109 |
| TrulicityDulaglutide | 17 | $13,755 |
| JanuviaSitagliptin Phosphate | 20 | $11,811 |
| Duloxetine Hcl | 261 | $11,729 |
| Aripiprazole | 60 | $10,843 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $17 | $122,78424 claims |
| Johnson & JohnsonRisperdal Consta, Xarelto | $67 | $56,23366 claims |
| AbbVieLinzess, Restasis | $321 | $42,94696 claims |
| Bausch Health US, LLCAplenzin | $88 | $31,21712 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $296 | $21,03112 claims |
| MerckJanuvia | $23 | $11,81120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 899 adult health providers in Pennsylvania.
Other adult health in Lima
- Beth SandyPhiladelphia$924K
- Diane NewmanPhiladelphia$413K
- Jennifer MondilloSchwenksville$396K
- Elizabeth FaustDouglassville$356K
- Abigail SmithPhiladelphia$302K
- Jean CainAllentown$214K
- Lauren MassimoPhiladelphia$139K
- Jennifer KeeleyWexford$97K
- Debra EvansFarrell$85K
- Bethann MallonBlue Bell$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.